ABSTRACT
Acute pharyngitis is a common illness that is responsible for 1% to 2% of all outpatient visits in the United States. 1 Viruses are the most common responsible etiologic agents, and usually the illness follows a benign, uncomplicated, self-limited course. Bacterial pharyngitis is less common, but the clinical course can be associated with significant complications. 2 Streptococcus pyogenes (β-hemolytic group A Streptococcus [GAS] ) is the primary agent of bacterial pharyngitis and accounts for 15% to 30% of cases in children and 5% to 15% of cases in adults of bacterial pharyngitis. 2, 3 Since patients with untreated streptococcal pharyngitis are at risk of developing nonsuppurative complications, such as acute rheumatic fever and glomerulonephritis, it is imperative that the diagnosis of GAS pharyngitis be made to initiate therapy rapidly.
It is difficult to distinguish between viral and bacterial causes of pharyngitis on the basis of history and physical examination alone 4 ; thus, it is recommended to test for GAS pharyngitis by rapid antigen detection tests (RADTs) and to perform a throat culture for patients with negative RADT results. [3] [4] [5] The RADTs are easy to perform and have a fast turnaround time, but their sensitivity in clinical practice varies and can be unacceptably low (range, 55%-100%) and thus the need for backup throat cultures on negative RADTs. [5] [6] [7] [8] [9] [10] The disadvantage of throat cultures is that they may take up to 48 hours to generate results, delaying appropriate antimicrobial treatment.
Nucleic acid testing offers an alternative method to improve speed and accuracy in the diagnosis of GAS pharyngitis and has been shown to have superior sensitivity and specificity.
In spring 2016, after a verification study of 200 throat specimens, our laboratory implemented the Solana GAS Assay (Quidel, San Diego, CA) that qualitatively detects group A β-hemolytic Streptococcus (S pyogenes) nucleic acids from throat swab specimens. The assay uses helicase-dependent amplification of the DNase B (sdaB) gene sequence and fluorescent probe-based detection in the Solana instrument to determine assay results. The nucleic acid amplification test (NAAT) was a substitute for backup culture on throat specimens with a negative rapid GAS antigen assay (McKesson Consult Diagnostics Strep A Test; McKesson, Richmond, VA). ESwab Liquid Amies Collection and Transport System (Copan Diagnostics, Murrieta, CA) were validated for use with the Solana GAS Assay and the traditional throat culture.
The aim of the study was to evaluate prospectively the performance of the Solana GAS Assay, after implementation in the laboratory, with conventional throat culture.
Materials and Methods

Specimen Collection and Processing
During the entire month of October 2016, all throat ESwabs from patients with a negative rapid GAS antigen assay from local urgent care center minute clinics were processed, within 24 hours of collection, by nucleic acid amplification testing (Solana GAS Assay), performed on the Solana instrument according to manufacturer instruction, and a standard throat culture for GAS was set up (sheep blood agar plates [Becton Dickinson, Sparks, MD] at 35°C, in 5% CO 2 ). The "hands-on" time for the NAAT per specimen was 7 minutes, and the total time to completion was 37 minutes.
The culture plates were reviewed at 24 and 48 hours; all β-hemolytic streptococci (consistent colony morphology, catalase negative) were purified to subculture plates and identified by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry VITEK MS (bioMérieux, Durham, NC). 14, 15 Two authors (S.A. and P.F.) performed all the culture reading, subculturing, and processing daily for 31 days.
Results
Of the 2,090 throat swab specimens tested, 116 (5.6%) were positive for GAS by culture and 136 (6.5%) were positive for GAS by NAAT; NAAT agreement with GAS culture result was 2,050 (98%) of 2,090. Ten samples were culture positive for GAS and NAAT negative; 30 specimens were negative for GAS by culture and positive by NAAT. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 91.4%, 98.5%, 78.0%, and 99.5%, respectively ❚Table 1❚, for the NAAT.
The positivity rate of the NAAT for GAS for the month of October 2016 (6.5% [136/2,090]) was comparable to the month of September 2016 (6.6% [153/2,325]) and the month of November 2016 (6.0% [130/2,167]).
Confirmatory Study in Our Laboratory of Discordant Results
The 40 discordant specimens were kept frozen at −70°C and retested by Solana GAS NAAT by one performer, and on repeat testing, eight of the 10 specimens, originally culture positive and NAAT negative for GAS, were now NAAT positive for GAS, and of the 30 specimens that were culture negative for GAS and NAAT positive, only 24 of the 30 specimens repeated positive for GAS by NAAT ❚Table 2❚. The two specimens of the 10 initially negative Solana specimens (all culture positive), which were not positive by NAAT upon repeat, were seen with specimens that had 1+ semiquantitation of GAS isolated by culture.
Preliminary Summary
Speculations for the original differences in NAAT positivity included nucleic acid stabilization issues, adequacy of specimen vortexing, reproducibility of the assay at the lower limit of detection, and other undefined variables.
Further Confirmatory Studies at Quidel R&D of Discordant Results
The 40 discordant specimens were also sent to Quidel R&D and tested by the Lyra Direct Strep Assay (Quidel, Athens, OH) and retested by the Solana GAS Assay. The target for GAS in the Lyra Direct Strep Assay is the putative competence (comX1.1) gene. The Lyra Direct Strep Assay is a real-time polymerase chain reaction assay for the rapid qualitative detection and differentiation of group A β-hemolytic Streptococcus (S pyogenes) and groups C and G β-hemolytic Streptococcus (examples: Streptococcus dysgalactiae, Streptococcus equi, Streptococcus canis) from throat specimens. There is no differentiation of group C from group G Streptococcus in this assay.
Thirty-eight of the 40 specimens tested with the Lyra Direct Strep Assay and the Solana GAS Assay at Quidel R&D gave concordant results between the two assays ( Table 2) . Of the two discordant specimens at Quidel R&D, one (specimen 7) was positive for GAS by the Lyra Direct Strep Assay only, and the other (specimen 38) was positive for GAS by the Solana GAS Assay only (Table 2 ). In our laboratory, both of these specimens were twice positive using the Solana GAS Assay.
According to the McKesson Consult Diagnostics Strep A Test instructional insert, the performance characteristics (95% confidence interval) of the assay are as follows: sensitivity, 97% (91%-99%); specificity, 95% (92%-97%); PPV, 86% (79%-91%); and NPV, 99% (97%-100%). In our study, the rapid antigen detection assay had a total failure rate of 6.75% compared with the NAAT/ culture results, with the highest failure rates found in the 5-to 9-year age group (13.3%) followed by the 10-to 14-year (9.9%) and the 0-to 4-year (9.3%) age groups ❚Table 3❚. These data were consistent with the RADTs' performance reported in the literature [5] [6] [7] [8] [9] [10] and in agreement with the necessity to perform supplementary testing for patients with negative RADT results.
Of interest, distribution of the 250 β-hemolytic streptococcal isolates recovered by culture included GAS (116/250, 46.4%), group B Streptococcus (68/250, 27.2%), groups C and G Streptococcus (identified to species level by MALDI-TOF mass spectrometry as S dysgalactiae, S dysgalactiae/equisimilis, S canis) (65/250, 26.0%), and one miscellaneous β-hemolytic streptococcal species (Streptococcus constellatus) (1/250, 0.4%).
Discussion
The detection of GAS by the Solana NAAT was more sensitive than rapid antigen detection assay and culture for GAS. The sensitivity of various rapid antigen detection assays for GAS ranges from 55% to 100%. 3, 9, 16 In our study, the RADT (McKesson Consult Diagnostics Strep A Test) failed to detect GAS in 141 throat specimens from symptomatic patients who sought care at local urgent care center clinics. The failure rate was higher in children than in adults (10.1% vs 3.0%). The backup throat cultures were able to detect 116 of the 141 GAS-positive throat specimens missed by the RADT but required between 24 and 48 hours to give an answer and demanded substantial hands-on time to process. The introduction of NAAT for the testing of GAS in clinical microbiology laboratories offers an alternative method that permits faster turnaround time and has greater sensitivity than RADTs and culture. Several molecular tests for the detection of GAS have been described in the literature reporting sensitivity and specificity greater than 97% 11, 13, 17, 18 with some exceptions. The recent study of the illumigene GAS assay (Meridian Bioscience, Cincinnati, OH) performance reported a sensitivity of 82% to 87%
19 compared with culture, which is lower than what had been reported by an earlier study using this molecular assay, where sensitivities were reported to be 98% to 100%. 20, 21 A recent study by Uphoff et al, 18 in which 1,081 throat samples were tested by culture and Solana GAS Assay, reported a sensitivity of 98.2% and a specificity of 97.2%.
Nevertheless, the high sensitivity of NAAT can be seen as a disadvantage by some physicians, as it may detect very small quantities of GAS that may represent only colonization and not true infection, and thus overtreatment of GAS will occur, with added expense, exposure to antibiotics, and interference with antibiotic stewardship initiatives.
A counterargument to this is that studies have shown specific GAS antibody development in patients with only 1+ to 2+ semiquantitative GAS cultures. 5 Thus, there may be benefits to detect lower quantities of GAS with exquisitely sensitive molecular technologies in symptomatic patients.
Conclusion
The consensus of the results, after the retesting of the 40 discordant specimens in our laboratory and at Quidel R&D, gave a final NAAT agreement with GAS culture results of 98.7% (2,063/2,090).
The two specimens that were positive for GAS by culture and negative by NAAT on primary testing repeated as negative by two different nucleic acid amplification assays. This discordance could be due to mutations in the GAS genome or GAS DNA present below the limits of detection in the two different assays.
The five specimens that tested positive for GAS by NAAT (culture negative) on primary testing and did not repeat as positive on subsequent NAAT testing could represent contamination during NAAT setup or nucleic acid stability issues during the freeze and thaw process. This emphasizes the importance of taking precautions against contamination of the work area and of maintaining a clean setup area. /culture  12  50  24  4  3  13  7  1  0  0  0  Positive NAAT only  1  11  7  1  1  3  0  1  0  0  0  Positive culture only  0  2  0  0  0  0  0  0  0  0  0  Total positive GAS  13  63  31  5  4  16  7  2  0  0  0  Negative GAS  126  411  280  176  267  349  212  94  23  10  1  Total tested  139  474  311  181  271  365  219  96  23  10 With two exceptions, 38 of 40 retested samples showed a high level of concordance between the Solana GAS Assay and the Lyra Direct GAS amplification assays when tested at Quidel R&D (Table 2) .
In summary, this postimplementation study, comprising a large number of specimens, supported high sensitivity and specificity of this GAS NAAT for throat swab specimens. The lower PPVs were likely due to greater sensitivity of the GAS NAAT compared with conventional throat culture for GAS. The results of this study favorably support that NAAT could be an alternative to culture to back up negative RADT results or possibly as a primary test for pharyngeal GAS with some exemptions (during rheumatic fever outbreaks, individuals with a history of rheumatic fever/rheumatic heart disease, members of families with individuals living in the household who have a history of rheumatic fever/rheumatic heart disease, etc). One of the main limiting factors of implementing NAAT GAS testing in point-of-care clinics is the technical expertise required to perform testing. The Solana group A streptococcal nucleic acid amplification assay is not a closed system and has moderate complexity. Thus, it requires considerable technical expertise in molecular testing to avoid contamination.
